^
Association details:
Biomarker:NRAS mutation
Cancer:Endometrial Cancer
Drug:AZ 628 (pan-RAF inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Title:

PI3K pathway dependencies in endometrioid endometrial cancer cell lines

Excerpt:
Three EEC cells showed SF50s below 1μM when treated with the selective RAF inhibitor AZD628 (Fig. 2D), and the presence of KRAS, HRAS or NRAS mutations was significantly associated with response to this agent (P=0.028), whilst KRAS mutations alone failed to show a statistically significant association (P=0.143).
DOI:
10.1158/1078-0432.CCR-12-3815